Vanda Pharmaceuticals Files 8-K on Financials
Ticker: VNDA · Form: 8-K · Filed: May 8, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | May 8, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Vanda Pharma dropped an 8-K on May 8th detailing their financial condition and operations. Check it for the latest numbers.
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037. The company is incorporated in Delaware and operates in the pharmaceutical preparations industry.
Why It Matters
This 8-K filing provides an update on Vanda Pharmaceuticals' financial condition and operational results, which is crucial information for investors and stakeholders to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not indicate any unusual or significant risks.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- May 8, 2024 (date) — Date of Report
- 2200 Pennsylvania Avenue NW Suite 300E Washington, DC 20037 (address) — Principal executive offices
- Delaware (jurisdiction) — State of incorporation
- 202-734-3400 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Vanda Pharmaceuticals Inc.'s results of operations and financial condition, including financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on May 8, 2024.
Where are Vanda Pharmaceuticals Inc.'s principal executive offices located?
Vanda Pharmaceuticals Inc.'s principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
In which state was Vanda Pharmaceuticals Inc. incorporated?
Vanda Pharmaceuticals Inc. was incorporated in Delaware.
What is the SIC code for Vanda Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Vanda Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,008 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2024-05-08 16:06:04
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Market
Filing Documents
- vnda-20240508.htm (8-K) — 37KB
- vnda8-k582024exhibit991.htm (EX-99.1) — 121KB
- vandaq32019earningsca_imaga.jpg (GRAPHIC) — 48KB
- 0001628280-24-021658.txt ( ) — 406KB
- vnda-20240508.xsd (EX-101.SCH) — 3KB
- vnda-20240508_def.xml (EX-101.DEF) — 16KB
- vnda-20240508_lab.xml (EX-101.LAB) — 28KB
- vnda-20240508_pre.xml (EX-101.PRE) — 16KB
- vnda-20240508_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 8, 2024, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended March 31, 2024 (the "Earnings Call"). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are "forward-looking statements" under the securities laws, including, but not limited to, statements regarding Vanda's commercial products, plans and opportunities, as well as statements about Vanda's products in development and the related clinical development and regulatory timelines and commercial potential for such products. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's assumptions regarding the strength of its business in the U.S. and Vanda's ability to complete the clinical development of, and obtain regulatory approval for, the products in its pipeline. Therefore, no assurance can be given that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements made during the Earnings Call should be evaluat
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated May 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 8, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary